Alumis is a clinical-stage biopharmaceutical company developing precision immunotherapies designed to replace broad immunosuppression with targeted treatments informed by genetic evidence and data analytics. The company's core pipeline includes Envu, a highly selective TYK2 inhibitor being advanced for psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases; and Lonigutamab, an IGF-1R monoclonal antibody for thyroid eye disease acquired through merger. Alumis has no current product revenue and relies on equity financing; the company plans to commercialize approved therapies in major markets either independently or through strategic partnerships, leveraging TYK2's genetic validation as a target across multiple immune-mediated conditions.